Doctor_Hari_Seldon Sunday, 10/14/18 02:25:48 PM Re: None Post # of 6548 Phase I of the clinical study is almost complete. No problems have been noted in this dose escalation safety and preliminary efficacy study of ISC-hpNSC®, intracranially transplanted patients with moderate Parkinson's disease. Phase II appears to be a certainty. This should be good for the stock, but more importantly for those suffering with Parkinsons and TBI (Traumatic Brain Injury, which the science is applicable to) lets hope for even moderate success. Any improvement, even if only to enhance and allow other treatments to be effective, is a big plus for any patient suffering from these debilitating neurological issues. I look forward to reading interim and long term results and to seeing Phase II studies underway. In the biotech world, few seldom take notice until Phase II studies are indeed underway. Science, for the betterment and improvement in the life of humankind and all that exist on this strange planet of ours. That pale blue dot, called home.